Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation

This study evaluates drug cost outcomes related to automatic therapeutic substitution of branded tobramycin solution for inhalation (TOBI(®)) with inhaled generic preservative-free intravenous tobramycin (PFIT). A retrospective single-center evaluation of inhaled tobramycin use from 2008 through 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Gauthier, Timothy P., Wasko, Justin, Unger, Nathan R., Abbo, Lilian M., Fernandez, Margaret, Aragon, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810404/
https://www.ncbi.nlm.nih.gov/pubmed/27025517
http://dx.doi.org/10.3390/antibiotics5010002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810404/
https://www.ncbi.nlm.nih.gov/pubmed/27025517
http://dx.doi.org/10.3390/antibiotics5010002

Ejemplares similares